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1. Introduction
  In most developing countries, tuberculosis (TB) is the most 
common cause of death among opportunistic infections 
associated with HIV infection[1]. Emergence of multi drug 
resistant (MDR) strains that are resistant to the two primary 
anti-tubercular drugs, isoniazid and rifampicin (RMP), 
have been reported worldwide[2]. Treatment of TB without 
information on the drug susceptibility pattern of the clinical 
isolate increases the risk of treatment failure and the spread 
of resistant strains. MDR-TB cannot be treated with first line 
drugs and its management using second line drugs requires 
proper organization[2]. Extensively drug resistant strains 
develop due to delay in diagnosis and mismanagement of 
MDR infections[3]. These strains lead to increased mortality 
and nosocomial out breaks[4]. Detection of resistance to RMP 
serves as a surrogate marker for diagnosis of MDR-TB[5].  
  Rapid liquid based systems like the non radiometric, 
fully automated MGIT960 systems are expensive and 
require specific bio-safety facilities, despite the low time 
to detection[6]. Genotypic nucleic acid amplification tests 
(NAAT), both commercial and in-house, are reported to have 
widespread inconsistencies[7]. Most forms of NAAT are more 
reliable with smear positive cases with high specificity and 
positive predictive value and hence can be used for ruling-
in TB[8]. The more recent Genotype MTBDRplus (Hain Life 
Sciences, Nehren, Germany) has excellent sensitivity and 
specificity for detecting RMP resistance[9]. Despite the 
advantages, the method is complex, expensive and requires 
specific facilities in terms of infra structure[10].
  Inexpensive direct sensitivity tests, based on direct 
inoculation of sputum deposit on the drug-containing 
Lowenstein-Jensen (LJ) slopes[11], give the susceptibility 
pattern of the isolates by 4 weeks, but they require a 
reasonable number of bacilli in the sample. Other less 
expensive drug susceptibility tests (DST) use redox indicator 
dyes[12] or measure levels of adenosine triphosphate (ATP)[13] 
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for quantifying mycobacterial growth. The results of the ATP 
bioluminescence assay did not compare well with that of 
conventional drug sensitivity test[14]. However, TB endemic 
regions where the laboratory resources are limited still 
depend on the standard DST using LJ medium that requires 
4-6 weeks for the results to become available.  
  The need of the hour is a rapid, reliable yet cost effective 
test that can substitute the conventional DST and can be 
useful for better management and treatment for patients with 
TB especially in program conditions. Reporter phages that 
detect viable microorganisms offer a specific tool for DST[15]. 
The present study was to evaluate luciferase reporter phage 
(LRP) construct phAE85 in rapid detection of RMP resistance 
in a region where TB is endemic.
   
2. Materials and methods
2.1. Drugs
  The antibiotic RMP (Sigma, MO) was initially dissolved in 
dimethyl formamide (Merck) and diluted in distilled water to 
obtain a concentration of 1 mg/mL and filtered through 0.45 
毺m membrane filter. Aliquots were stored at -80 曟 till use. 
2.2. LRP
  LRP phAE85 was used in the study. The construct was 
propagated and titrated on lawns of Mycobacterium 
tuberculosis (M. tuberculosis) mc2155[16] as previously 
described[17].
 
2.3. Cultures used
  Primary isolates of M. tuberculosis grown on LJ medium 
were selected as soon as growth was observed. One hundred 
ninety cultures were included in the study.
2.4. DST
 Conventional minimum inhibitory concentration (MIC) 
method was performed using standard protocol[18].
2.5. DST by LRP method
  The M. tuberculosis isolates were coded for LRP assay. 
Suspension of growth was prepared in sterile Middlebrook 
7H9 medium and the turbidity was adjusted to #2 
McFarland’s standard. About 100 毺L of the suspension was 
added separately to two vials containing 350 毺L of 7H9 
medium (control) and 350 毺L of 7H9 medium containing 
RMP at a final concentration of 2 毺g/mL (test). 
  The cultures were incubated at 37 曟 for 72 h after which 
50 毺L of phAE85 was added at a multiplicity of infection 
of 10. After a further incubation of 3-4 h, 100 毺L of the 
cell phage suspension was mixed with an equal volume of 
0.33 mmol/L D-luciferin (Sigma, MO) in 0.05 mol/L sodium 
citrate buffer at pH 4.5 in a cuvette. Light output was 
measured immediately in a luminometer (Monolight® Model 
2010 Analytical Luminescence Laboratory, Ann Arbour, MI) 
as relative light units (RLU) at 10 s integration. Duplicate 
readings were taken for all the vials. Categorization of 
cultures was done based on standardization experiments. 
Cultures showing more than 50% reduction in RLU in ‘test’ 
compared to ‘control’ were classified as sensitive and less 
than 50% reduction were considered as resistant.
  Whenever the mean RLU of the controls was less than 1 000, 
the experiment was repeated. Susceptibility patterns of the 
strains were compared with conventional assay results. 
Cultures of M. tuberculosis H37Rv and duplicates of 10% 
cultures were doubly coded and repeated as internal quality 
controls. 
2.6. Statistical analysis
  Results of conventional LJ and LRP assay were analyzed 
using SPSS software version 14.0. Statistical tests included 
Chi square, Kappa, and Fisher exact test. The test was based 
on 95% confidence interval. 
 
3. Results
3.1. Phage propagation and titre
  LRP phAE85 was propagated in bulk and stored at 4 °C. A 
titre of 5伊108 pfu/mL was used throughout the assay.
3.2. Phage infection and light production
  All 190 strains of M. tuberculosis were found to be 
susceptible to infection by the LRP construct phAE85 and 
all of them yielded measurable RLUs using the luminometer. 
Less than 10% of cultures yielded <1 000 RLU with the 
control and the assay was repeated for all of them using 
heavy inoculum. 
3.3. Conventional LJ
  Among 190 cultures used, 34 strains were reported as 
resistant and the remaining 154 strains were reported as 
susceptible by conventional LJ method. 
3.4. DST by LRP
  Among the 190 cultures tested, 34 strains were reported as 
resistant to the drug by the conventional method. Among 
them, 31 (91%) were identified as resistant by the LRP assay. 
Among the remaining 156 susceptible cultures, LRP assay 
identified 154 strains as susceptible and 2 as resistant (99%) 
(Table 1). 
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Table 1
Susceptibility to rifampicin by conventional minimum inhibitory 
concentration (MIC) and luciferase reporter phage (LRP) assay.
LRP
Conventional MIC
Resistant Sensitive Total
Resistant 31     2   33
Sensitive   3 154 157
Total 34 156 190
  
  Comparison between the test and the conventional LJ 
medium showed high level of agreement of 97% (CI 0.94, 0.99) 
and P value was 0.000 1. The sensitivity and specificity of 
LRP assay for detection of RMP resistance were 91% (CI 0.75, 
0.98) and 99% (CI 0.95, 1.00) respectively. The positive and 
negative predictive values of the assay were 94% (CI 0.78, 
0.99) and 98% (CI 0.94, 1.00) respectively. Internal quality 
control cultures yielded 100% reproducible results. Time to 
detection of resistance was 3 d using the primary isolate in 
comparison with 28 d for the MIC method. 
 
4. Discussion
  Potential of the LRP phAE85 in drug susceptibility assays 
has already been demonstrated by using microwell plate 
and by applying photo film based detection in a Bronx 
box[19]. In the current study, LRP was evaluated using a tube 
luminometer in a TB endemic area. This instrument yields 
definitive and quantitative results unlike the Bronx-box 
which offers semi quantitative results and is dependant on 
visual interpretation. Such interpretation may yield false 
results especially in borderline resistant strains. Further, 
with highly sensitive variations of the luminometer being 
available including portable models, such an evaluation 
would aid in establishing a field friendly method for drug 
susceptibility testing in even remote areas.  
  The TM4 based phage construct, phAE85, is known to 
produce 3-10 times higher RLU consistently compared 
to the first generation reporter phage phAE40 infecting 
M. tuberculosis[20]. The sensitivity and specificity of LRP-
DST assay were 92% and 99%. These values were within 
the range reported by Pai et al[21] for LRP-DST using other 
recombinant phage constructs and methodologies. The 
agreement with the indirect sensitivity tests was 97% and 
corresponded closely to that reported for MGIT960 system for 
determination of resistance to RMP at critical concentration 
in comparison with conventional resistance ratio method[22]. 
Discrepant cultures when repeated by both methods yielded 
no change in the results. Reproducibility of the test was 
found to be high with internal quality control cultures 
yielding results 100% similar to original results.  
  In the current study, LRP-DST yielded five discrepant 
results out of 190 cultures. False susceptibility was reported 
in three strains that exhibited low level resistance by the 
conventional method. Instance of broth based detection 
systems such as BACTEC 460 and BACTEC MGIT 960 
yielding false susceptible results for low level resistant 
strains have been reported earlier[23]. Two true susceptible 
strains were reported as false resistant. This discordance is 
perhaps due to the inherent differences in the methods of 
inoculation employed by both methods. While LRP assay is 
performed using sterile aerosol barrier tips, MIC is usually 
performed using sterile loops where presence of one micro 
colony of the growth in either could influence the outcome 
of the test. Such discordance arising due to differences 
between the methodologies adopted has been reported[24]. 
  Van Deun et al. suggested the use of simple screening 
techniques as no single test is complete and accurate 
with respect to detection of drug resistant TB[25]. The LRP 
assay in its present form has low reagent costs and is 
simple to perform. Given the high specificity of the LRP-
DST using phAE85, i.e., its high positive predictive value 
for resistant strains, it could be used to arrive at more 
appropriate therapies. The assay does not depend on 
expensive, highly sensitive instruments like BACTEC MGIT 
960 or the genotypic methods which require specific infra 
structure facilities and supplies that limit its application in 
resource limited settings. Further, WHO recommends use 
of NAATs only for screening smear positive cases for RMP 
resistance[26]. Dependence on DST using primary culture still 
exists in smear negative cases and for treatment monitoring. 
Rapidity of LRP-DST with a time to detection of 3 d in 
comparison with 28-42 d for the conventional methods 
makes it more appealing in program conditions. Possibility 
of performing the test as an in-house semi automated assay 
makes it more attractive for medium level laboratories. 
Multi-centric evaluation of the procedure and feasibility 
studies for decentralization of the technique may pave the 
way for introduction of LRP-DST in National Tuberculosis 
Control Programs as low cost screening technology for smear 
negative cases as well as for treatment monitoring of MDR 
TB patients.  
  The present study uses LRP assay as a rapid drug 
susceptibility assay for detection of MDR-TB in an endemic 
setting. LRP assay with phAE85 is 99% specific, 91% 
sensitive and is highly reproducible. Thus, the assay offers 
a simple procedure for drug sensitivity testing, within the 
scope of semi-automation. Wherever it is possible to obtain 
a culture on solid media, it can be performed with relative 
accuracy, speed, ease, and low cost.
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